Epitranscriptomic Regulation by m6A in Metabolic Reprogramming and Cellular Plasticity during Cancer Progression
Open Access
- 30 September 2025
- journal article
- Published by Drug Targets and Therapeutics (DTT) - Pharmaceutical Society of Korea in Drug Targets and Therapeutics
- Vol. 4 (2) , 148-156
Abstract
Arathy Vasukutty, Poshan Yugal Bhattarai, Hong Seok Choi. DTT 2025;4:148-56. https://doi.org/10.58502/DTT.25.0015Keywords
Funding Information
- Chosun University
This publication has 81 references indexed in Scilit:
- Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized OpportunitiesAdvanced Science, 2024
- YTHDF1 regulates GID8-mediated glutamine metabolism to promote colorectal cancer progression in m6A-dependent mannerCancer Letters, 2024
- Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancersMolecular and Cellular Biochemistry, 2024
- Silencing of METTL3 suppressed ferroptosis of myocardial cells by m6A modification of SLC7A11 in a YTHDF2 mannerJournal of Bioenergetics and Biomembranes, 2024
- N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implicationsBiomedicine & Pharmacotherapy, 2023
- RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A‐YTHDF2‐dependent mannerClinical and Translational Medicine, 2023
- Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionCancer Cell, 2020
- The role of mitochondria in metabolism and cell deathBiochemical and Biophysical Research Communications, 2017
- FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA DemethylaseCancer Cell, 2017
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012